Regulation of apoptosis and proliferation in Ewing's sarcoma--opportunities for targeted therapy
- PMID: 16400699
- DOI: 10.1002/hon.766
Regulation of apoptosis and proliferation in Ewing's sarcoma--opportunities for targeted therapy
Abstract
The Ewing's sarcoma family of tumors are malignant tumors of bone and soft tissue which occur predominantely in children and adolescents. Whereas cure rates for patients with localized tumors are around 70%, survival rates for patients with metastases or relapse are poor in spite of intensive chemo- and radiation therapy, demonstrating a clear need for new, more effective therapies. Insights into the biology of the tumors of the Ewing's sarcoma family with identification of the EWS/ETS gene rearrangement as the key event in malignant transformation and its influence on the regulation of various pathways involved in proliferation, differentiation and apoptosis has led to the identification of potential targets for the development of new molecular therapeutics. This review will focus on the regulation of major pathways of proliferation and apoptosis in tumors of the Ewing's sarcoma family and point out how modulation of these pathways might be of potential use for future therapy.
Copyright 2005 John Wiley & Sons, Ltd.
Similar articles
-
DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.Oncogene. 2008 Oct 9;27(46):6034-43. doi: 10.1038/onc.2008.203. Epub 2008 Jun 30. Oncogene. 2008. PMID: 18591936
-
GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.Oncogene. 2009 Nov 19;28(46):4126-32. doi: 10.1038/onc.2009.262. Epub 2009 Aug 31. Oncogene. 2009. PMID: 19718047
-
EWS/FLI1 regulates tumor angiogenesis in Ewing's sarcoma via suppression of thrombospondins.Cancer Res. 2007 Jul 15;67(14):6675-84. doi: 10.1158/0008-5472.CAN-06-4140. Cancer Res. 2007. PMID: 17638877
-
Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future.Curr Opin Oncol. 2008 Jul;20(4):412-8. doi: 10.1097/CCO.0b013e328303ba1d. Curr Opin Oncol. 2008. PMID: 18525337 Review.
-
The Biology of Ewing sarcoma.Cancer Lett. 2007 Aug 28;254(1):1-10. doi: 10.1016/j.canlet.2006.12.009. Epub 2007 Jan 23. Cancer Lett. 2007. PMID: 17250957 Review.
Cited by
-
Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.Br J Cancer. 2010 Oct 26;103(9):1380-90. doi: 10.1038/sj.bjc.6605896. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877355 Free PMC article.
-
Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma.Paediatr Drugs. 2008;10(2):93-105. doi: 10.2165/00148581-200810020-00004. Paediatr Drugs. 2008. PMID: 18345719 Review.
-
Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1.Med Oncol. 2010 Dec;27(4):1096-101. doi: 10.1007/s12032-009-9341-6. Epub 2009 Oct 27. Med Oncol. 2010. PMID: 19859844
-
The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26. Pathol Oncol Res. 2011. PMID: 21267687
-
Unusual Manifestation of Extraosseous Ewing Sarcoma: Report of 3 Cases.Balkan J Med Genet. 2023 May 2;25(2):77-81. doi: 10.2478/bjmg-2022-0022. eCollection 2023 May. Balkan J Med Genet. 2023. PMID: 37265973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical